Robert Z Orlowski

List of Publications by Citations

259 papers	26,313 citations	70 h-index	160 g-index
269 ext. papers	30,475 ext. citations	7.3 avg, IF	6.65 L-index

#	Paper	IF	Citations
259	A phase 2 study of bortezomib in relapsed, refractory myeloma. *New England Journal of Medicine*, **2003**, 348, 2609-17	59.2	2196
258	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncology, The*, **2016**, 17, e328-e346	21.7	1155
257	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology*, **2015**, 33, 2863-9	2.2	976
256	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 621-31	59.2	935
255	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *New England Journal of Medicine*, **2016**, 375, 1319-1331	59.2	930
254	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood*, **2011**, 117, 4691-5	2.2	681
253	Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. *Journal of Clinical Oncology*, **2002**, 20, 4420-7	2.2	645
252	Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. *Blood*, **2007**, 110, 3281-90	2.2	591
251	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet, The*, **2016**, 387, 1551-1560	40	581
250	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
249	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncology, The*, **2016**, 17, 27-38	21.7	576
248	Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *Journal of Clinical Oncology*, **2007**, 25, 3892-901	2.2	551
247	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*, **2012**, 120, 2817-25	2.2	544
246	Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. *Journal of Clinical Oncology*, **2006**, 24, 3113-20	2.2	529
245	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet, The*, **2017**, 389, 519-527	40	496
244	NF-kappaB as a therapeutic target in cancer. *Trends in Molecular Medicine*, **2002**, 8, 385-9	11.5	487
243	Proteasome inhibitors in cancer therapy: lessons from the first decade. *Clinical Cancer Research*, **2008**, 14, 1649-57	12.9	485

242	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*, **2016**, 127, 2955-62	2.2	463
241	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood*, **2011**, 118, 4771-9	2.2	453
240	Proteasome inhibitors in cancer therapy. *Nature Reviews Clinical Oncology*, **2017**, 14, 417-433	19.4	437
239	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *New England Journal of Medicine*, **2019**, 380, 2104-2115	59.2	435
238	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. *Cancer Cell*, **2012**, 22, 345-58	24.3	393
237	Proteasome inhibitors in multiple myeloma: 10 years later. *Blood*, **2012**, 120, 947-59	2.2	370
236	American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. *Journal of Clinical Oncology*, **2007**, 25, 2464-72	2.2	350
235	The role of the ubiquitin-proteasome pathway in apoptosis. *Cell Death and Differentiation*, **1999**, 6, 303-13	12.7	326
234	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. *Blood*, **2005**, 106, 3777-84	2.2	278
233	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncology, The*, **2017**, 18, e206-e217	21.7	275
232	The proteasome as a target for cancer therapy. *Clinical Cancer Research*, **2003**, 9, 6316-25	12.9	267
231	Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. *Blood*, **2005**, 105, 3058-65	2.2	266
230	In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. *Clinical Cancer Research*, **2011**, 17, 5311-21	12.9	256
229	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *Journal of Clinical Oncology*, **2014**, 32, 587-600	2.2	255
228	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 1327-1337	21.7	248
227	A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. *Clinical Cancer Research*, **2009**, 15, 7085-91	12.9	242
226	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood*, **2011**, 117, 6063-73	2.2	234
225	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. *Blood*, **2012**, 119, 5661-70	2.2	209

224	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. *Journal of Clinical Oncology*, **2016**, 34, 1544-57	2.2	204
223	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 1311-8	21.7	199
222	Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. *Cancer*, **2005**, 103, 1195-200	6.4	199
221	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*, **2020**, 136, 936-945	2.2	189
220	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. *Blood*, **2015**, 126, 2284-90	2.2	174
219	Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. *Blood*, **2009**, 113, 4667-76	2.2	174
218	IMWG consensus on maintenance therapy in multiple myeloma. *Blood*, **2012**, 119, 3003-15	2.2	150
217	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. *Clinical Cancer Research*, **2017**, 23, 3307-3315	12.9	148
216	An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. *British Journal of Haematology*, **2012**, 158, 739-48	4.5	144
215	Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. *Blood*, **2012**, 120, 3260-70	2.2	140
214	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). *Blood*, **2014**, 123, 78-85	2.2	135
213	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. *Clinical Cancer Research*, **2016**, 22, 34-43	12.9	127
212	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. *British Journal of Haematology*, **2013**, 161, 357-66	4.5	120
211	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Blood*, **2013**, 122, 3122-8	2.2	119
210	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2039-2051	4.7	114
209	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. *Science Signaling*, **2016**, 9, ra17	8.8	105
208	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood*, **2014**, 123, 4136-42	2.2	102
207	Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. *Clinical Cancer Research*, **2007**, 13, 6469-78	12.9	102

206	The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. *Breast Cancer Research*, **2003**, 5, 1-7	8.3	102
205	A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. *Cancer Cell*, **2013**, 24, 791-805	24.3	101
204	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2017**, 177, 457-466	4.5	100
203	An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 310-8	2	97
202	Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. *Journal of Biological Chemistry*, **2002**, 277, 27864-71	5.4	96
201	Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. *Journal of Biological Chemistry*, **2011**, 286, 11009-20	5.4	95
200	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. *American Journal of Hematology*, **2015**, 90, 42-9	7.1	92
199	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. *Clinical Cancer Research*, **2017**, 23, 2891-2904	12.9	90
198	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. *Blood*, **2017** , 129, 1658-1668	2.2	88
197	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1126-1137	2.2	88
196	Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. *Oncotarget*, **2015**, 6, 34329-41	3.3	87
195	Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. *Blood*, **2015**, 126, 2475-8	2.2	85
194	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. *Blood*, **2014**, 123, 632-9	2.2	81
193	Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. *British Journal of Haematology*, **2009**, 145, 481-90	4.5	79
192	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 1317-1330	21.7	76
191	Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Clinical Cancer Research*, **2013**, 19, 2248-56	12.9	73
190	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. *Cancer Cell*, **2017**, 32, 88-100.e6	24.3	72
189	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). *Blood Cancer Journal*, **2020**, 10, 53	7	68

188	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. *Cancer Cell*, **2016**, 29, 639-652	24.3	67
187	A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. *Blood*, **2014**, 124, 2687-97	2.2	66
186	Feasibility of autologous hematopoietic stem cell transplant in patients aged ⩾70 years with multiple myeloma. *Leukemia and Lymphoma*, **2012**, 53, 118-22	1.9	65
185	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. *Cancer*, **2008**, 112, 1529-37	6.4	65
184	Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. *British Journal of Haematology*, **2011**, 152, 579-92	4.5	63
183	The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. *Cancer*, **2020**, 126, 3192-3201	6.4	59
182	p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. *Cancer Research*, **2012**, 72, 6393-402	10.1	58
181	Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. *Breast Cancer Research and Treatment*, **2006**, 100, 33-47	4.4	58
180	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. *Blood*, **2015**, 126, 505-505	2.2	58
179	The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. *Journal of Biological Chemistry*, **2015**, 290, 29854-68	5.4	55
178	Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. *Leukemia*, **2018**, 32, 2224-2239	10.7	53
177	Osteoblastic niche supports the growth of quiescent multiple myeloma cells. *Blood*, **2014**, 123, 2204-8	2.2	53
176	Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. *Molecular and Cellular Biology*, **2014**, 34, 3435-49	4.8	53
175	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. *Annals of Hematology*, **2010**, 89, 1133-40	3	50
174	Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. *Clinical Lymphoma and Myeloma*, **2008**, 8, 352-5		50
173	Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. *Clinical Cancer Research*, **2014**, 20, 3174-86	12.9	47
172	Crystal-storing histiocytosis: a clinicopathological study of 13 cases. *Histopathology*, **2016**, 68, 482-91	7.3	46
171	Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. *Clinical Cancer Research*, **2014**, 20, 1366-74	12.9	45

170	CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. *Cancer Research*, **2012**, 72, 4225-37	10.1	44
169	Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. *Molecular Cancer Therapeutics*, **2012**, 11, 2243-53	6.1	43
168	Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. *Annals of Hematology*, **2007**, 86, 211-6	3	41
167	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. *Nature Communications*, **2015**, 6, 8428	17.4	39
166	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 17	7	39
165	Effect of long-term storage in TRIzol on microarray-based gene expression profiling. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2445-52	4	39
164	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. *Blood*, **2015**, 126, 25-25	2.2	39
163	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. *British Journal of Haematology*, **2017**, 178, 547-560	4.5	38
162	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. *Lancet Haematology,the*, **2021**, 8, e45-e54	14.6	38
161	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. *British Journal of Haematology*, **2019**, 186, e117-e121	4.5	37
160	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e266-e275	14.6	36
159	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. *Blood Cancer Journal*, **2018**, 8, 67	7	36
158	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer Journal*, **2020**, 10, 91	7	36
157	Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. *Journal of Hematology and Oncology*, **2014**, 7, 41	22.4	35
156	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. *Cancer*, **2012**, 118, 2507-15	6.4	35
155	Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. *Seminars in Oncology*, **2013**, 40, 634-51	5.5	34
154	RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. *British Journal of Haematology*, **2017**, 177, 80-94	4.5	33
153	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. *Science Translational Medicine*, **2019**, 11,	17.5	33

152	Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. *Blood*, **2019**, 133, 1572-1584	2.2	33
151	HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. *Blood*, **2011**, 118, 4140-9	2.2	33
150	Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. *Leukemia and Lymphoma*, **2015**, 56, 602-7	1.9	32
149	A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. *Cancer*, **2017**, 123, 4617-4630	6.4	32
148	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. *Haematologica*, **2015**, 100, 100-6	6.6	31
147	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. *Cancer*, **2016**, 122, 2050-6	6.4	30
146	Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. *British Journal of Haematology*, **2016**, 172, 889-901	4.5	29
145	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 522-530.e1	2	28
144	Why proteasome inhibitors cannot ERADicate multiple myeloma. *Cancer Cell*, **2013**, 24, 275-7	24.3	28
143	Antigen-mediated regulation in monoclonal gammopathies and myeloma. *JCI Insight*, **2018**, 3,	9.9	28
142	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. *Leukemia and Lymphoma*, **2016**, 57, 1104-13	1.9	27
141	Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 110-4	2	27
140	Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. *Clinical Cancer Research*, **2008**, 14, 5416-25	12.9	27
139	Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. *Clinical Cancer Research*, **2016**, 22, 4901-4912	12.9	26
138	Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13 Suppl 2, S317-29	2	26
137	The ubiquitin proteasome pathway from bench to bedside. *Hematology American Society of Hematology Education Program*, **2005**, 2005, 220-5	3.1	26
136	Future agents and treatment directions in multiple myeloma. *Expert Review of Hematology*, **2014**, 7, 127-48	2	25
135	Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1227-32	4.7	25

134	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). *Blood*, **2018**, 132, LBA-2-LBA-2	2.2	25
133	Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. *Leukemia and Lymphoma*, **2015**, 56, 1335-41	1.9	24
132	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *American Journal of Hematology*, **2012**, 87, 272-6	7.1	24
131	Activating , , and mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 20004-20014	11.5	23
130	New Drugs in Multiple Myeloma. *Annual Review of Medicine*, **2019**, 70, 521-547	17.4	22
129	Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. *PLoS ONE*, **2014**, 9, e89064	3.7	22
128	Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. *PLoS ONE*, **2014**, 9, e103015	3.7	22
127	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. *Blood Advances*, **2019**, 3, 2400-2408	7.8	22
126	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 687-93	2	21
125	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 472-6	2	21
124	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. *British Journal of Haematology*, **2013**, 163, 611-20	4.5	20
123	A sensitive procedure for determination of cathepsin D: activity in alveolar and peritoneal macrophages. *Molecular and Cellular Biochemistry*, **1984**, 64, 155-62	4.2	20
122	Anti-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. *Oncotarget*, **2015**, 6, 8567-78	3.3	20
121	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. *Cancer*, **2016**, 122, 3831-3837	6.4	20
120	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. *British Journal of Cancer*, **2018**, 118, 388-397	8.7	20
119	A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. *Cancer Medicine*, **2014**, 3, 1275-83	4.8	19
118	Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 625-31	5	19
117	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 1582-1596	21.7	19

116	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. *Clinical Pharmacokinetics*, **2018**, 57, 529-538	6.2	18
115	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation* , **2018**, 24, 2197-2203	4.7	18
114	Targeting the proteasome as a therapeutic strategy against haematological malignancies. *Expert Opinion on Investigational Drugs*, **2006**, 15, 117-30	5.9	17
113	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. *Oncotarget*, **2017**, 8, 59476-59491	3.3	17
112	Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. *Cancer*, **2015**, 121, 1138-46	6.4	16
111	The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 346, 381-92	4.7	16
110	Novel approaches to treatment of double-refractory multiple myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**,	7.1	16
109	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. *Clinical Cancer Research*, **2015**, 21, 2538-45	12.9	15
108	A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1453-8	4.7	15
107	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2159-2164	4.7	15
106	Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. *Annals of Hematology*, **2017**, 96, 977-985	3	14
105	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leukemia and Lymphoma*, **2015**, 56, 1723-6	1.9	14
104	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. *American Journal of Hematology*, **2016**, 91, E442-7	7.1	14
103	The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. *Neoplasia*, **2017**, 19, 772-780	6.4	14
102	C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. *Science Signaling*, **2017**, 10,	8.8	14
101	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). *Blood*, **2019**, 134, 3116-3116	2.2	14
100	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia **2016**, 4, 90		14
99	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. *Bone Marrow Transplantation*, **2019**, 54, 1089-1093	4.4	14

98	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. *Lancet Haematology,the*, **2017**, 4, e283-e292	14.6	13
97	Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. *International Journal of Cancer*, **2015**, 136, 991-1002	7.5	13
96	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. *Blood*, **2015**, 126, 4222-4222	2.2	13
95	Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. *Oncotarget*, **2017**, 8, 73723-73732	3.3	13
94	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1609-1618	4	13
93	Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. *Leukemia Research*, **2015**, 39, 371-9	2.7	12
92	A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 80	7	11
91	Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. *Neoplasia*, **2015**, 17, 289-300	6.4	11
90	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. *Cancer*, **2018**, 124, 2561-2569	6.4	11
89	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. *Leukemia and Lymphoma*, **2019**, 60, 442-452	1.9	11
88	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. *Journal of Hematology and Oncology*, **2015**, 8, 74	22.4	11
87	Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. *Molecular Cancer Therapeutics*, **2011**, 10, 148-58	6.1	11
86	Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. *Lancet Haematology,the*, **2018**, 5, e628-e640	14.6	11
85	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 424-432	2	10
84	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 560-569	2	10
83	Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. *British Journal of Haematology*, **2015**, 171, 373-7	4.5	10
82	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. *Blood*, **2009**, 114, 2878-2878	2.2	10
81	Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 1982-1982	2.2	10

80	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. *PLoS Medicine*, **2020**, 17, e1003323	11.6	10
79	Once-weekly (70 mg/m) vs twice-weekly (56 mg/m) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. *Cancer Medicine*, **2020**, 9, 2989-2996	4.8	9
78	Targeting Myddosome Signaling in Waldenstrm's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. *Clinical Cancer Research*, **2018**, 24, 6408-6420	12.9	9
77	Proteasome inhibitors in cancer therapy. *Methods in Molecular Biology*, **2005**, 301, 339-50	1.4	9
76	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. *Cancer*, **2017**, 123, 3568-3575	6.4	8
75	Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 459-473	5.5	8
74	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. *Leukemia Research*, **2014**, 38, 896-900	2.7	8
73	Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). *Blood* , **2018**, 132, 1982-1982	2.2	8
72	Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). *Blood*, **2012**, 120, 1868-1868	2.2	8
71	Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstrm's macroglobulinemia. *Leukemia and Lymphoma*, **2019**, 60, 964-970	1.9	8
70	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. *Cell Metabolism*, **2021**, 33, 78-93.e7	24.6	8
69	Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. *Modern Pathology*, **2017**, 30, 843-853	9.8	7
68	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e221-e238	2	7
67	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged 75 years. *Leukemia and Lymphoma*, **2019**, 60, 3536-3543	1.9	7
66	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e353-e354	2	7
65	Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. *British Journal of Haematology*, **2017**, 179, 503-506	4.5	7
64	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. *Annals of Hematology*, **2015**, 94, 1605-7	3	7
63	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 665-671	4.7	7

62	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. *European Journal of Haematology*, **2016**, 97, 342-7	3.8	7
61	Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. *European Journal of Haematology*, **2017**, 99, 119-132	3.8	6
60	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. *Leukemia and Lymphoma*, **2018**, 59, 1364-1374	1.9	6
59	Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics. *Cancer Informatics*, **2014**, 13, 113-23	2.4	6
58	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 3969-3978	12.9	6
57	Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. *Haematologica*, **2020**, 105, e242-e245	6.6	5
56	Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. *Acta Haematologica*, **2018**, 139, 67-70	2.7	5
55	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 3155-3155	2.2	5
54	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. *Blood Advances*, **2020**, 4, 181-190	7.8	5
53	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. *Blood Advances*, **2020**, 4, 4834-4837	7.8	5
52	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1413-7	4.7	4
51	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 36-42	2	4
50	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. *Annals of Hematology*, **2019**, 98, 2233-2235	3	4
49	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. *Leukemia and Lymphoma*, **2014**, 55, 11-8	1.9	4
48	Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. *Modern Pathology*, **2017**, 30, 1378-1386	9.8	4
47	Longer Term Follow up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). *Blood*, **2018**, 132, 1992-1992	2.2	4
46	A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. *Blood*, **2010**, 116, 1959-1959	2.2	4
45	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. *Neoplasia*, **2021**, 23, 361-374	6.4	4

44	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. *Journal of Clinical Oncology*, **2021**, 39, 227-237	2.2	4
43	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. *Leukemia and Lymphoma*, **2018**, 59, 515-518	1.9	3
42	Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma. *Journal of Managed Care & Specialty Pharmacy*, **2018**, 24, 487	1.9	3
41	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. *European Journal of Haematology*, **2017**, 98, 263-268	3.8	3
40	Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.. *Blood*, **2005**, 106, 1576-1576	2.2	3
39	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. *Journal of Molecular Medicine*, **2020**, 98, 1161-1173	5.5	3
38	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 797-803	2	3
37	Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors. *Frontiers in Immunology*, **2020**, 11, 1816	8.4	3
36	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. *Clinical Cancer Research*, **2019**, 25, 6781-6787	12.9	3
35	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. *American Journal of Hematology*, **2019**, 94, E2-E5	7.1	3
34	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. *Haematologica*, **2020**, 105, e355-e357	6.6	3
33	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. *Haematologica*, **2021**, 106, 3211-3214	6.6	3
32	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e465-e469	2	2
31	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. *JCO Oncology Practice*, **2020**, 16, e1169-e1180	2.3	2
30	Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, e302-e306	7.1	2
29	Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. *Blood*, **2012**, 120, 75-75	2.2	2
28	Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial. *Blood*, **2015**, 126, 875-875	2.2	2
27	Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. *Blood*, **2016**, 128, 5628-5628	2.2	2

26	Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. *Neoplasia*, **2021**, 24, 1-11	6.4	2
25	Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. *Clinical Cancer Research*, **2020**, 26, 5814-5819	12.9	2
24	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. *British Journal of Haematology*, **2021**, 193, e23-e26	4.5	2
23	Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. *Supportive Care in Cancer*, **2021**, 29, 467-475	3.9	2
22	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. *Blood Cancer Journal*, **2021**, 11, 17	7	2
21	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2
20	SARS-CoV-2 in multiple myeloma: initial observation and management. *Leukemia and Lymphoma*, **2020**, 61, 2763-2766	1.9	1
19	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2011**, 118, 333-333	2.2	1
18	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. *Modern Pathology*, **2021**, 34, 327-335	9.8	1
17	Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. *Cancer Drug Resistance (Alhambra, Calif.)*, **2021**, 4, 888-902	4.5	1
16	A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *American Journal of Hematology*, **2019**, 94, E319-E322	7.1	0
15	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. *Leukemia and Lymphoma*, **2021**, 1-12	1.9	0
14	Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2020**, 95, E232-E235	7.1	0
13	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. *Oncotarget*, **2017**, 8, 41620-41630	3.3	0
12	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1077-1083	4.7	0
11	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 243.e1-243.e6		0
10	Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. *Supportive Care in Cancer*, **2021**, 29, 6099-6107	3.9	0
9	A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. *American Journal of Hematology*, **2021**, 96, E243-E246	7.1	0

8	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. *American Journal of Hematology*, **2019**, 94, E72-E74	7.1	0
7	Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. *Current Oncology*, **2022**, 29, 2954-2972	2.8	0
6	Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. *Resistance To Targeted Anti-cancer Therapeutics*, **2014**, 81-98	0.3	
5	The future of proteasome inhibitors in relapsed/refractory multiple myeloma. *Oncology*, **2011**, 25 Suppl 2, 56-64	1.8	
4	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. *American Journal of Cancer Research*, **2021**, 11, 3285-3293	4.4	
3	A Systematic Review Evaluating the Addition of Radiation Therapy to Chemotherapy for Localized Aggressive Non-Hodgkin Lymphoma: What Is the Role for Radiotherapy?.. *Blood*, **2004**, 104, 3155-3155	2.2	
2	Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. *Oncotarget*, **2017**, 8, 113858-113873	3.3	
1	Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. *Cancer Epidemiology*, **2021**, 73, 101972	2.8	